Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.61 |
| ▸ | DPP8 | Q6V1X1 | 9/20 | 0.61 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.61 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.61 |
| ▸ | ACE | P12821 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | FAP | Q12884 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16993655 | 1.00 | DPP4 (0.61) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL23269993 | 1.00 | DPP4 (0.61) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL30104180 | 1.00 | DPP4 (0.61) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL19042587 | 0.90 | DPP4 (0.59) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL19042589 | 0.88 | DPP4 (0.57) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL19036875 | 0.85 | DPP4 (0.46) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL14919832 | 0.83 | DPP4 (0.66) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL1136100 | 0.82 | DPP4 (0.62) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL30406108 | 0.82 | DPP4 (0.62) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL1136102 | 0.82 | DPP4 (0.62) | DPP4DPP8DPP7DPP9ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115754078-A | Method for detecting related substances of sitagliptin phosphate | 湖北省宏源药业科技股份有限公司 | 2023-03-07 | — | — | CN | claimed |
| CN-115754078-B | Method for detecting sitagliptin phosphate related substances | 湖北省宏源药业科技股份有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-117883447-A | Sitagliptin metformin sustained release tablet | 南京正大天晴制药有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-114075201-B | Preparation method of sitagliptin impurity | 北京新康哌森医药科技有限公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-115754078-A | Method for detecting related substances of sitagliptin phosphate | 湖北省宏源药业科技股份有限公司 | 2023-03-07 | — | — | CN | disclosed |
| US-20220387427-A1 | ORAL GLIPTIN COMPOSITIONS AND METHOD FOR PREPARATION THEREOF | PHARMA-DATA RESEARCH AND DEVELOPMENT SINGLE MEMBER S.A. (GR) | 2022-12-08 | — | — | US | disclosed |
| CN-114075201-A | Preparation method of sitagliptin impurity | 北京新康哌森医药科技有限公司 | 2022-02-22 | — | — | CN | disclosed |
| WO-2020130502-A1 | PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN AND SITAGLIPTIN | (주)휴온스 | 2020-06-25 | — | — | WO | disclosed |
| US-9938282-B2 | Expedient synthesis of sitagliptin | STEREOKEM, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9938282-B2 | Expedient synthesis of sitagliptin | STEREOKEM, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9938282-B2 | Expedient synthesis of sitagliptin | STEREOKEM, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170183351-A1 | EXPEDIENT SYNTHESIS OF SITAGLIPTIN | STEREOKEM, INC. | 2017-06-29 | — | — | US | disclosed |
| US-20170183351-A1 | EXPEDIENT SYNTHESIS OF SITAGLIPTIN | STEREOKEM, INC. | 2017-06-29 | — | — | US | disclosed |
| US-20170183351-A1 | EXPEDIENT SYNTHESIS OF SITAGLIPTIN | STEREOKEM, INC. | 2017-06-29 | — | — | US | disclosed |
| EP-3102580-A2 | EXPEDIENT SYNTHESIS OF SITAGLIPTIN | Stereokem Inc. (USA) (US) | 2016-12-14 | — | — | EP | disclosed |
| WO-2015120111-A2 | EXPEDIENT SYNTHESIS OF SITAGLIPTIN | STEREOKEM, INC. (USA) (US) | 2015-08-13 | — | — | WO | disclosed |
| WO-2015120111-A2 | EXPEDIENT SYNTHESIS OF SITAGLIPTIN | STEREOKEM, INC. (USA) (US) | 2015-08-13 | — | — | WO | disclosed |
| WO-2011060213-A2 | PREPARATION OF SITAGLIPTIN AND SALTS THEREOF | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-05-19 | — | — | WO | disclosed |
| WO-2010122578-A2 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN AND ITS INTERMEDIATES | MSN LABORATORIES LIMITED (IN) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183351-A1 | EXPEDIENT SYNTHESIS OF SITAGLIPTIN | DPP4, DPP7, DPP8 | DPP4 1/4885DPP8 3/4885DPP7 2/4885 |
| US-20220387427-A1 | ORAL GLIPTIN COMPOSITIONS AND METHOD FOR PREPARATION THEREOF | GCG, GLI2, GCKR | DPP4 83/4885DPP8 67/4885DPP7 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.